Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 35.86% is 13% above its 5-year average of 31.70%, near the high end of its 5-year range (-145.50%–86.30%).
As of the fiscal period ended Tuesday, June 30, 2026. 402.27% above its 12-month average of -11.86%.
Reported quarterly gross margin; no daily interpolation.
GROSS MARGIN
35.86%
GROSS MARGIN AVG TTM
-11.86%
GROSS MARGIN AVG 3Y
30.19%
GROSS MARGIN AVG 5Y
48.62%
GROSS MARGIN AVG 10Y
57.51%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+402.27%
CURRENT VS 3Y AVG
+18.78%
CURRENT VS 5Y AVG
-26.24%
CURRENT VS 10Y AVG
-37.64%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
59.09%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-39.31%
vs the sector median at left
Market Cap
$21.98B
Gross Margin
86.58%
TTM Avg
88.58%
3Y Avg
89.63%
5Y Avg
90.66%
Market Cap
$24.00B
Gross Margin
36.77%
TTM Avg
35.27%
3Y Avg
37.10%
5Y Avg
37.60%
Market Cap
$24.23B
Gross Margin
92.62%
TTM Avg
92.70%
3Y Avg
93.10%
5Y Avg
93.74%
Market Cap
$24.59B
Gross Margin
55.02%
TTM Avg
58.60%
3Y Avg
58.69%
5Y Avg
58.45%
Market Cap
$18.17B
Gross Margin
61.62%
TTM Avg
66.54%
3Y Avg
68.95%
5Y Avg
69.55%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | $21.75B | 35.86% | -11.86% | 30.19% | 48.62% |
| United Therapeutics Corporation (UTHR)vs › | $21.98B | 86.58% | 88.58% | 89.63% | 90.66% |
| STERIS plc (STE)vs › | $22.26B | 44.25% | 44.13% | 43.77% | 43.82% |
| BioNTech SE (BNTX)vs › | $22.91B | 73.26% | 78.98% | 81.24% | 82.89% |
| Viatris Inc. (VTRS)vs › | $20.45B | 34.40% | 36.61% | 38.73% | 36.31% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.00B | 36.77% | 35.27% | 37.10% | 37.60% |
| Incyte Corporation (INCY)vs › | $24.23B | 92.62% | 92.70% | 93.10% | 93.74% |
| Waters Corporation (WAT)vs › | $24.59B | 55.02% | 58.60% | 58.69% | 58.45% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.17B | 61.62% | 66.54% | 68.95% | 69.55% |
| Labcorp Holdings Inc. (LH)vs › | $25.35B | 28.38% | 27.30% | 28.39% | 31.16% |
Gross Margin
35.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 35.86% |
| 2026-03-31 | -145.50% |
| 2025-12-31 | 33.33% |
| 2025-09-30 | 0.79% |
| 2025-06-30 | 16.20% |
| 2025-03-31 | 15.89% |
| 2024-12-31 | 22.70% |
| 2024-09-30 | 72.29% |
| 2024-06-30 | 47.96% |
| 2024-03-31 | 42.51% |
| 2023-12-31 | 66.97% |
| 2023-09-30 | -22.39% |
| 2023-06-30 | -112.50% |
| 2023-03-31 | 56.91% |
| 2022-12-31 | 62.75% |
| 2022-09-30 | 65.84% |
| 2022-06-30 | 69.75% |
| 2022-03-31 | 82.88% |
| 2021-12-31 | 86.30% |
| 2021-09-30 | 85.05% |
| 2021-06-30 | 82.21% |
| 2021-03-31 | 88.93% |
| 2020-12-31 | 97.26% |
| 2020-09-30 | 94.62% |
| 2020-06-30 | 88.55% |
| 2020-03-31 | 11.21% |
| 2019-12-31 | 36.40% |
| 2019-09-30 | 57.17% |
| 2019-06-30 | 42.67% |
| 2019-03-31 | 54.35% |
| 2018-12-31 | 79.25% |
| 2018-09-30 | 84.48% |
| 2018-06-30 | -262.13% |
| 2018-03-31 | -210.36% |
| 2017-12-31 | 93.56% |
| 2017-09-30 | 87.92% |
| 2017-06-30 | -178.55% |
| 2017-03-31 | -178.55% |
